Pediatric neurology · 2014
Clinical experience with long-term acetazolamide treatment in children with nondystrophic myotonias: a three-case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Markhorst Joekie M, Stunnenberg Bas C, Ginjaar Ieke B, Drost Gea, Erasmus Corrie E, Sie Lilian T L
Аннотация
BACKGROUND: Today, treatment of the nondystrophic myotonias consists of mexiletine, although care has to be taken because of the proarrhythmogenic potential of this drug. In this article, we report years of experience with the carbonic anhydrase inhibitor acetazolamide.
PATIENTS: We present three children with nondystrophic myotonias.
RESULTS: During acetazolamide treatment, symptoms and signs of myotonia decreased in our children.
CONCLUSIONS: Based on this clinical experience and the favorable pharmacologic profile of acetazolamide, it may be a good treatment option for children with nondystrophic myotonias.
PATIENTS: We present three children with nondystrophic myotonias.
RESULTS: During acetazolamide treatment, symptoms and signs of myotonia decreased in our children.
CONCLUSIONS: Based on this clinical experience and the favorable pharmacologic profile of acetazolamide, it may be a good treatment option for children with nondystrophic myotonias.